Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Clarithromycin,Rifabutin,Clofazimine

            Therapeutic Area: Gastroenterology Product Name: RHB-104

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: H.C. Wainwright & Co.

            Deal Size: $10.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering March 01, 2021

            Details:

            The Company intends to use the net proceeds from this offering to fund its clinical development programs, commercialization activities and for acquisitions and general corporate purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Clarithromycin,Rifabutin,Clofazimine

            Therapeutic Area: Gastroenterology Product Name: RHB-204

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: H.C. Wainwright & Co.

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Public Offering January 11, 2021

            Details:

            The Company intends to use the net proceeds from this offering to fund its clinical development programs, commercialization activities and for acquisitions and general corporate purposes.